Potential resistance of SARS-CoV-2 main protease (Mpro) against protease inhibitors: lessons learned from HIV-1 protease

JA Mótyán, M Mahdi, G Hoffka, J Tőzsér - International journal of …, 2022 - mdpi.com
Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome 2
(SARS-CoV-2), has been one of the most devastating pandemics of recent times. The lack of …

Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel

MS Hirsch, HF Günthard, JM Schapiro… - Clinical Infectious …, 2008 - academic.oup.com
Resistance to antiretroviral drugs remains an important limitation to successful human
immunodeficiency virus type 1 (HIV-1) therapy. Resistance testing can improve treatment …

Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a …

L Wittkop, HF Günthard, F De Wolf, D Dunn… - The Lancet infectious …, 2011 - thelancet.com
Background The effect of transmitted drug resistance (TDR) on first-line combination
antiretroviral therapy (cART) for HIV-1 needs further study to inform choice of optimum drug …

Flexible parametric models for relative survival, with application in coronary heart disease

CP Nelson, PC Lambert, IB Squire… - Statistics in …, 2007 - Wiley Online Library
Relative survival is frequently used in population‐based studies as a method for estimating
disease‐related mortality without the need for information on cause of death. We propose an …

Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a …

RL Hamers, R Schuurman, KCE Sigaloff… - The Lancet infectious …, 2012 - thelancet.com
Background The effect of pretreatment HIV-1 drug resistance on the response to first-line
combination antiretroviral therapy (ART) in sub-Saharan Africa has not been assessed. We …

[PDF][PDF] European recommendations for the clinical use of HIV drug resistance testing: 2011 update

AM Vandamme, RJ Camacho, F Ceccherini-Silberstein… - Aids Rev, 2011 - academia.edu
Abstract The European HIV Drug Resistance Guidelines Panel, established to make
recommendations to clinicians and virologists, felt that sufficient new information has …

Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1–infected …

DR Kuritzkes, CM Lalama, HJ Ribaudo… - The Journal of …, 2008 - academic.oup.com
A case-cohort study was used to determine the effect of baseline nonnucleoside reverse-
transcriptase inhibitor (NNRTI) resistance, as assessed by viral genoty**, on the response …

A novel methodology for large-scale phylogeny partition

MCF Prosperi, M Ciccozzi, I Fanti, F Saladini… - Nature …, 2011 - nature.com
Understanding the determinants of virus transmission is a fundamental step for effective
design of screening and intervention strategies to control viral epidemics. Phylogenetic …

Doravirine suppresses common nonnucleoside reverse transcriptase inhibitor-associated mutants at clinically relevant concentrations

M Feng, NA Sachs, M Xu, J Grobler… - Antimicrobial agents …, 2016 - Am Soc Microbiol
Doravirine (DOR), which is currently in a phase 3 clinical trial, is a novel human
immunodeficiency type 1 virus (HIV-1) nonnucleoside reverse transcriptase inhibitor …

Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey

S Yerly, V von Wyl, B Ledergerber, J Böni… - Aids, 2007 - journals.lww.com
Objectives: Representative prevalence data of transmitted drug-resistant HIV-1 are essential
to establish accurate guidelines addressing resistance testing and first-line treatments …